Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-18), Fluicell AB's 14-Day RSI is 46.51.
The industry rank for Fluicell AB's 14-Day RSI or its related term are showing as below:
OSTO:FLUI's 14-Day RSI is ranked worse than 63.83% of 1424
companies
in the Biotechnology industry
Industry Median: 47.285
vs OSTO:FLUI: 46.51
Fluicell AB (OSTO:FLUI) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Fluicell AB 14-Day RSI Related Terms
OSTO:FLUI vs VRTX, REGN, ALNY: 14-Day RSI Comparison
For the Biotechnology subindustry, Fluicell AB's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fluicell AB 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fluicell AB's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Fluicell AB's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fluicell AB (OSTO:FLUI) has a 14-Day RSI of 46.51 as of Jul. 18, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Fluicell AB and its competitors. According to the industry distribution chart, Fluicell AB ranks #909 out of 1424 companies in the Biotechnology industry, placing it in the top 63.8%.
Is Fluicell AB's 14-Day RSI too high?
Fluicell AB's current 14-Day RSI is 46.51. The Biotechnology industry median 14-Day RSI is 47.29. Fluicell AB's value of 46.51 is 1.6% below this industry median. Based on the distribution chart, Fluicell AB ranks #909 out of 1424 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Fluicell AB has a GF Score™ of 51/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fluicell AB's 14-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Fluicell AB ranks #909 out of 1424 companies for 14-Day RSI. This places Fluicell AB in the lower half of its industry. The industry median 14-Day RSI is 47.29. Fluicell AB's value of 46.51 is 1.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 47.29, based on 1,424 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fluicell AB's current 14-Day RSI of 46.51 is 1.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Fluicell AB and its competitors. For the Biotechnology industry, the median 14-Day RSI is 47.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fluicell AB's current 14-Day RSI is 46.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fluicell AB stock overvalued right now?
Based on GuruFocus' analysis, Fluicell AB (OSTO:FLUI) is currently considered Fairly Valued. The stock's GF Value™ is kr34.23, compared to a current price of kr33.00 — trading 3.6% below its estimated fair value. The current 14-Day RSI is 46.51 and 1.6% below the Biotechnology industry median of 47.29. Fluicell AB's overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Fluicell AB (OSTO:FLUI), the current 14-Day RSI is 46.51 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fluicell AB (OSTO:FLUI) Overvalued in 2026?
Based on GuruFocus' analysis, Fluicell AB stock appears to be undervalued.
The current stock price of kr33.00 is trading 3.6% below its estimated GF Value™ of kr34.23.
GuruFocus considers Fluicell AB to be Fairly Valued.
Key valuation signals for OSTO:FLUI:
14-Day RSI: 46.51
GF Value™: kr34.23 vs. price of kr33.00 (3.6% below fair value)
Industry Position: 1.6% below the Biotechnology median (#909 of 1424)
No single metric tells the full story. See the OSTO:FLUI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fluicell AB is a Swedish life science company that conducts development in regenerative medicine and human tissue-based screening models for drug development, with a particular focus on the areas of type 1 diabetes, cardiac safety screening models, and kidney diseases. The company's platform for the production of human tissue that is based on Fluicell's technology for high-resolution 3D bioprinting, and which enables the creation of tissue-based products for use in drug development and regenerative medicine.
51GF Score
Get the complete analysis for OSTO:FLUI
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:FLUI has been successfully added to your 
